Electra Therapeutics nets $183M to fund pivotal ELA026 sHLH trial

Electra Therapeutics has secured a major late-stage financing, closing a $183 million Series C that will bankroll a registrational study of its lead drug and accelerate a second programme into clinical testing. The round was co-led by EQT Life Sciences and Nextech, with strategic participation from corporate and institutional backers.

Proceeds will primarily underwrite a global Phase 2/3 registrational trial of the company’s lead antibody, ELA026, in secondary hemophagocytic lymphohistiocytosis (sHLH) — a rapidly progressive, often fatal hyperinflammatory syndrome with no broadly approved therapies. The financing will also help validate clinical activity for a second SIRP-targeted programme, ELA822, and support early expansion into related haematologic malignancies.

Electra’s approach focuses on selectively removing immune cells that sustain runaway inflammation while preserving normal immune functions. In an early clinical signal that helped underpin investor interest, frontline-treated patients in a Phase 1b cohort showed 100% survival at 8 weeks. The lead asset has won regulatory attention, holding both FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.

Management framed the round as a de-risking milestone. Kathy Dong, President and CEO of Electra, said the capital will enable the company to run a registrational programme with the statistical power and geographic reach necessary for global filings, while advancing the second SIRP-directed molecule toward proof-of-mechanism in human disease.

From an investor perspective, the syndicate mixes specialist life-science investors and strategic partners. Alongside the co-leads, the financing included participation from names such as Sanofi, HBM Healthcare Investments and Mubadala Capital, together with earlier backers. Christoph Broja, a partner with EQT Life Sciences and incoming board observer, described the biology and early human data as the combination that persuaded the fund to lead the round.

Immunology and targeted immuno-oncology programmes that show translational proof are attracting outsized interest compared with earlier, discovery-stage platforms.

For patients and the market, a successful registrational trial would fill an acute unmet need. In cancer-associated sHLH, eight-week survival with current management is roughly 50% in published series; a demonstrably effective, well-tolerated therapy could rapidly reset standards of care and open additional indications across inflammatory and haematologic disease space. Electra now has the financial runway to test that hypothesis at scale — and the sector will be watching how the Phase 2/3 readout shapes both clinical practice and investor appetite.